MML Investors Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.3M | Buy |
18,117
+1,108
| +7% | +$754K | 0.02% | 592 |
|
|
2026
Q1 | $13.1M | Sell |
17,009
-2,869
| -14% | -$2.2M | 0.04% | 455 |
|
|
2025
Q4 | $15.3M | Buy |
19,878
+1,029
| +5% | +$699K | 0.04% | 434 |
|
|
2025
Q3 | $10.6M | Buy |
18,849
+3,470
| +23% | +$1.96M | 0.03% | 523 |
|
|
2025
Q2 | $8.07M | Buy |
15,379
+7,033
| +84% | +$3.93M | 0.02% | 598 |
|
|
2025
Q1 | $5.29M | Buy |
8,346
+813
| +11% | +$559K | 0.02% | 705 |
|
|
2024
Q4 | $5.37M | Buy |
7,533
+2,218
| +42% | +$1.86M | 0.02% | 680 |
|
|
2024
Q3 | $5.59M | Buy |
5,315
+648
| +14% | +$721K | 0.02% | 639 |
|
|
2024
Q2 | $4.91M | Sell |
4,667
-736
| -14% | -$713K | 0.02% | 633 |
|
|
2024
Q1 | $5.2M | Sell |
5,403
-176
| -3% | -$167K | 0.02% | 625 |
|
|
2023
Q4 | $4.9M | Buy |
5,579
+1,387
| +33% | +$1.14M | 0.02% | 600 |
|
|
2023
Q3 | $3.45M | Buy |
4,192
+1,688
| +67% | +$1.33M | 0.02% | 681 |
|
|
2023
Q2 | $1.8M | Buy |
2,504
+349
| +16% | +$269K | 0.01% | 949 |
|
|
2023
Q1 | $1.77M | Sell |
2,155
-341
| -14% | -$257K | 0.01% | 832 |
|
|
2022
Q4 | $1.8M | Sell |
2,496
-119
| -5% | -$87.8K | 0.01% | 871 |
|
|
2022
Q3 | $1.8M | Sell |
2,615
-70
| -3% | -$44.1K | 0.01% | 797 |
|
|
2022
Q2 | $1.59M | Buy |
2,685
+286
| +12% | +$186K | 0.01% | 843 |
|
|
2022
Q1 | $1.68M | Sell |
2,399
-1,215
| -34% | -$769K | 0.01% | 868 |
|
|
2021
Q4 | $2.28M | Buy |
3,614
+574
| +19% | +$353K | 0.02% | 708 |
|
|
2021
Q3 | $1.84M | Sell |
3,040
-5,169
| -63% | -$3.21M | 0.01% | 760 |
|
|
2021
Q2 | $4.58M | Buy |
8,209
+70
| +0.9% | +$35.5K | 0.04% | 419 |
|
|
2021
Q1 | $3.85M | Buy |
8,139
+4,664
| +134% | +$2.27M | 0.04% | 426 |
|
|
2020
Q4 | $1.68M | Sell |
3,475
-155
| -4% | -$83.7K | 0.02% | 646 |
|
|
2020
Q3 | $2.03M | Buy |
3,630
+157
| +5% | +$95.2K | 0.03% | 517 |
|
|
2020
Q2 | $2.17M | Buy |
3,473
+1,210
| +53% | +$687K | 0.03% | 473 |
|
|
2020
Q1 | $1.1M | Sell |
2,263
-1,716
| -43% | -$708K | 0.02% | 594 |
|
|
2019
Q4 | $1.49M | Sell |
3,979
-60
| -1% | -$20.2K | 0.02% | 571 |
|
|
2019
Q3 | $1.12M | Sell |
4,039
-1,394
| -26% | -$413K | 0.02% | 633 |
|
|
2019
Q2 | $1.7M | Sell |
5,433
-120
| -2% | -$40K | 0.02% | 547 |
|
|
2019
Q1 | $2.28M | Sell |
5,553
-1,641
| -23% | -$676K | 0.04% | 416 |
|
|
2018
Q4 | $2.69M | Sell |
7,194
-420
| -6% | -$154K | 0.05% | 343 |
|
|
2018
Q3 | $3.08M | Buy |
7,614
+1,560
| +26% | +$594K | 0.05% | 323 |
|
|
2018
Q2 | $2.09M | Sell |
6,054
-21
| -0.3% | -$6.57K | 0.05% | 340 |
|
|
2018
Q1 | $2.09M | Buy |
6,075
+1,344
| +28% | +$467K | 0.04% | 340 |
|
|
2017
Q4 | $1.78M | Buy |
4,731
+774
| +20% | +$313K | 0.03% | 377 |
|
|
2017
Q3 | $1.77M | Buy |
3,957
+123
| +3% | +$58.5K | 0.04% | 355 |
|
|
2017
Q2 | $1.88M | Buy |
3,834
+1,136
| +42% | +$497K | 0.04% | 341 |
|
|
2017
Q1 | $1.05M | Buy |
+2,698
| New | +$1M | 0.02% | 263 |
|
Other funds holding REGN
MML Investors Services's REGN Position: Q2 2026 in Review
MML Investors Services increased its Regeneron Pharmaceuticals (REGN) stake by 6.5% in Q2 2026, buying an estimated $754K and bringing the position to 18,117 shares worth $11.3M. The position accounts for 0.02% of the portfolio, ranked #592.
MML Investors Services first reported a position in REGN in Q1 2017 and has held it in 38 quarters since. The position peaked at $15.3M in Q4 2025. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- MML Investors Services held 18,117 shares of Regeneron Pharmaceuticals worth $11.3M as of Q2 2026.
- MML Investors Services bought 1,108 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $754K.
- Regeneron Pharmaceuticals made up 0.02% of MML Investors Services's portfolio in Q2 2026, its #592 holding.
- MML Investors Services first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
- MML Investors Services's Regeneron Pharmaceuticals position peaked at $15.3M in Q4 2025.
- 729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.